Considerations in Darbepoetin alfa Cost and Reimbursement: A Model for Pharmacy Managers

Pharmacotherapy

Volumn 23, Issue 12 II, 2003, Pages

  Anderson Jr , Ernest R ^a   Gibson, Gene ^b  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Darbepoetin alfa; Pharmacoeconomics; Reimbursement analysis

Indexed keywords

ANTINEOPLASTIC AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BUDGET; CANCER CHEMOTHERAPY; DRUG COST; DRUG FORMULARY; ERYTHROCYTE TRANSFUSION; FATIGUE; HEALTH INSURANCE; HUMAN; MEDICAID; MEDICAL STAFF; MEDICARE; QUALITY OF LIFE; REIMBURSEMENT; REVIEW;

AMBULATORY CARE; COST-BENEFIT ANALYSIS; DRUG COSTS; EPOETIN ALFA; ERYTHROPOIETIN; HEMATINICS; INSURANCE, HEALTH, REIMBURSEMENT; PHARMACEUTICAL SERVICES; REIMBURSEMENT MECHANISMS;

EID: 0345305418     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.16.119S.31972     Document Type: Review

References (14)

1. Bodenheimer TS, Grumbach K. Understanding health policy, 3rd ed. New York: McGraw-Hill; 2002.
2. Korcok M. Malpractice fee hikes mean some U.S. MDs can't afford to work. Can Med Assoc J 2003;168:472.
3. Valley AW. Overview of cancer-related anemia: focus on the potential role of darbepoetin alfa. Pharmacotherapy 2002;22(9 pt 2):S150-9.
4. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:1-25.
5. Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy, Cancer 2002;95:888-95.
6. Scott SD. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies. Pharmacotherapy 2002;22(9 pt 2):S160-5.
7. Zamboni WC, Stewart CF. An overview of the pharmacokinetic disposition of darbepoetin alfa. Pharmacotherapy 2002;22(9 pt 2):S133-40.
8. Glaspy JA. Overcoming barriers to erythropoietic therapy. Oncology 2002;16:S71-7.
9. Amgen Inc. Aranesp (darbepoetin alfa) package insert. Thousand Oaks, CA; 2002.
10. Mirtsching B, Charu V, Vadhan-Raj S, et al. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia: results of a combined analysis. Oncology 2002;16:S31-6.
11. Glaspy JA, Tchekmedyian NS. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology 2002;16(10 suppl 11):23-9.
12. Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 to 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002;87:268-76.
13. Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics 2001;19:609-21.
14. Sanchez LA. Applied pharmacoeconomics: evaluation and use of pharmacoeconomic data from literature. Am J Health-Syst Pharm 1999;56:1630-40.